Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Do you recommend consolidation immunotherapy after SBRT or surgery and chemo for T1-T2N0 SCLC?
Related Questions
What are your top takeaways in thoracic cancers from ESMO 2025?
What is the recommendation for persistent PET uptake and elevated catecholamines at 4 months following subtotal resection and adjuvant radiation for a thoracic secretory paraganglioma?
How does neoadjuvant chemo-immunotherapy impact your decision on hypofractionation/dose fractionation for locally advanced NSCLC, now getting RT alone?
Can palliative radiation be used to treat recurrent malignant pleural effusion in NSCLC?
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
Do you restrict the dose rate during treatment delivery to a pacemaker in addition to limiting the Dmax?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
In a patient who underwent cryoablation for early NSCLC, is there a role for giving preemptive further local therapy?
What target expansions do you use when treating with 60 Gy in 15 fractions for the lung?
Is there a concern for using FFF beams in single isocenter multi target lung SBRT?
